Back

Empagliflozin treatment pre- and post- acute myocardial infarction reduces no-reflow, inflammatory cell infiltration and infarct size while preserving cardiac function.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Basic research in acute coronary syndromes No Reflow ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Panagiota Efstathia Nikolaou

National & Kapodistrian University of Athens, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Carvedilol suppresses coronary artery spasm in A-kinase anchoring protein 150 knockout mouse
Doctor Y. Konno (Hirosaki, JP)
Abstract Slides Video
Presentation thumbnail
Nonalcoholic fatty liver disease worsens cardiac repair after myocardial infarction
Doctor F. Hamidou (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Mortality related to left ventricular ejection fraction and obstructive coronary artery disease in non-ST-segment elevation myocardial infarction
Doctor N. Stoedkilde-Joergensen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
TLR7 deficiency alleviated myocardial ischemia reperfusion injury via regulating macrophage-neutrophil interaction
Doctor Y. Lai (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Soluble amyloid precursor protein-alpha mediates post-ischemic neovascularization after myocardial infarction
Doctor H. Kawase (Bad Nauheim, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Basic research in acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Potential cardio-protective role of dapagliflozin in diabetic patients presented with anterior ST-elevation myocardial infarction (STEMI).
thumbnail
Congress Presentation
Empagliflozin improves metabolic profile and prevents myocardial and coronary dysfunction in diabetic rat hearts subjected to ischemia/reperfusion injury
thumbnail
Congress Presentation
Anti-inflammatory protection of early vs delayed sodium-glucose cotransporter-2 inhibitor therapy on monocyte-derived macrophages from patients with type2 diabetes with acute myocardial infarction.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources